• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment outcomes in extensively resistant tuberculosis.

作者信息

Chan Edward D, Strand Matthew J, Iseman Michael D

出版信息

N Engl J Med. 2008 Aug 7;359(6):657-9. doi: 10.1056/NEJMc0706556.

DOI:10.1056/NEJMc0706556
PMID:18687654
Abstract
摘要

相似文献

1
Treatment outcomes in extensively resistant tuberculosis.广泛耐药结核病的治疗结果
N Engl J Med. 2008 Aug 7;359(6):657-9. doi: 10.1056/NEJMc0706556.
2
Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.广泛耐药结核病比耐多药结核病更严重：方法和背景不同，但结果相同。
Clin Infect Dis. 2008 Mar 15;46(6):958-9. doi: 10.1086/528875.
3
Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.对氟喹诺酮类药物和链霉素耐药但对二线注射治疗敏感的耐多药结核病，其预后比广泛耐药结核病更好。
Clin Infect Dis. 2009 Mar 1;48(5):e50-2. doi: 10.1086/597010.
4
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.关于《每日300毫克利奈唑胺治疗难治性耐多药和广泛耐药结核病》的评论
J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8.
5
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病——作者回应
J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10.
6
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.未感染艾滋病毒的耐多药和广泛耐药结核病患者的治疗结果。
Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005.
7
The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis.手术及氟喹诺酮类药物在耐多药结核病治疗中的作用
Int J Tuberc Lung Dis. 2007 Sep;11(9):979-85.
8
State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.耐药结核病的最新进展系列：是时候保护氟喹诺酮类药物了。
Int J Tuberc Lung Dis. 2009 Nov;13(11):1319.
9
Promising candidates in clinical trials against multidrug-resistant tuberculosis (MDR-TB) based on natural products.基于天然产物的抗多重耐药结核病（MDR-TB）临床试验有前途的候选药物。
Fitoterapia. 2009 Dec;80(8):453-60. doi: 10.1016/j.fitote.2009.07.010. Epub 2009 Aug 19.
10
Drug resistance in tuberculosis and options available.结核病中的耐药性及可用的应对方案。
J Indian Med Assoc. 2010 Feb;108(2):106-8.

引用本文的文献

1
Treatment outcomes and associated influencing factors among elderly patients with rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study in China.老年耐利福平肺结核患者的治疗结局及相关影响因素：一项中国的多中心、回顾性队列研究
BMC Infect Dis. 2025 Sep 1;25(1):1086. doi: 10.1186/s12879-025-11491-4.
2
Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.印度广泛耐药结核病：关于诊断与管理的当前证据
Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16.
3
Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India.
印度孟买一组接受耐多药结核病治疗的 HIV 感染青少年的不良结局。
PLoS One. 2013 Jul 19;8(7):e68869. doi: 10.1371/journal.pone.0068869. Print 2013.
4
Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India.印度农村地区医科和护理专业学生结核特异性干扰素-γ释放试验反应轨迹
J Epidemiol Glob Health. 2013 Jun;3(2):105-17. doi: 10.1016/j.jegh.2013.03.003. Epub 2013 Apr 10.
5
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials.非甾体抗炎药使结核分枝杆菌对内源性和外源性抗菌药物敏感。
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11. doi: 10.1073/pnas.1214188109. Epub 2012 Sep 10.
6
Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes.结核分枝杆菌的毒力取决于脂酰脱氢酶，它是三个多酶复合物的成员之一。
Cell Host Microbe. 2011 Jan 20;9(1):21-31. doi: 10.1016/j.chom.2010.12.004.
7
Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.广泛耐药结核病：时代的标志与抗菌药物研发的动力
Pharmaceuticals (Basel). 2010 Jul 1;3(7):2268-2290. doi: 10.3390/ph3072268.
8
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.广泛耐药结核病的出现：需要新干预措施的全球卫生危机：第一部分：问题的起源和性质。
Clin Transl Sci. 2008 Dec;1(3):249-54. doi: 10.1111/j.1752-8062.2008.00060.x.
9
Risk factors for MDR and XDR-TB in a tertiary referral hospital in India.印度一家三级转诊医院中耐多药和广泛耐药结核病的危险因素。
PLoS One. 2010 Mar 4;5(3):e9527. doi: 10.1371/journal.pone.0009527.
10
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.用于耐多药（MDR）和广泛耐药（XDR）结核病管理的二线和三线抗结核药物的临床药理学及病灶穿透特性
Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797.